Monogram Orthopaedics, Inc. Share Price

Equities

MGRM

US6097861081

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:30:00 16/05/2024 BST 5-day change 1st Jan Change
2.13 USD +3.40% Intraday chart for Monogram Orthopaedics, Inc. +9.23% -38.08%
Sales 2024 * 1.11M 87.66M Sales 2025 * 5.66M 447M Capitalization 67.38M 5.32B
Net income 2024 * -13M -1.03B Net income 2025 * -16M -1.26B EV / Sales 2024 * 60.7 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 11.9 x
P/E ratio 2024 *
-4.95 x
P/E ratio 2025 *
-4.18 x
Employees 28
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.02%
More Fundamentals * Assessed data
Dynamic Chart
Monogram Orthopaedics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Monogram Orthopaedics Inc. Provides Regulatory Update Following Meeting with FDA CI
Top Premarket Decliners MT
Monogram Orthopaedics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Monogram Orthopaedics, Inc. Elects Colleen Gray to Its Board CI
Monogram Orthopaedics, Inc. Delivers First Surgical Robot CI
Certain Common Stock of Monogram Orthopaedics, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2023. CI
Top Premarket Decliners MT
Monogram Orthopaedics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Monogram Orthopaedics Files Shelf for Up to 6.5 Million Common Shares MT
Monogram Orthopaedics Inc. Announces Completion of the Development Phase and the Start of the Verification Phase for its Next-Generation Autonomous Surgical Robotic System CI
Monogram Orthopaedics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Monogram Orthopaedics, Inc. announced that it expects to receive $19.999997 million in funding from B. Riley Principal Capital II, LLC CI
Monogram Orthopaedics Receives Conditional Purchase Order to Begin Pilot Program With Global Distributor MT
Monogram Orthopaedics Inc. Secures First Conditional Purchase Order to Initiate Pilot Program with Global Distributor CI
More news
1 day+3.40%
1 week+9.23%
Current month+3.15%
1 month-18.70%
3 months-31.73%
6 months-23.10%
Current year-38.08%
More quotes
1 week
1.87
Extreme 1.87
2.20
1 month
1.82
Extreme 1.82
2.65
Current year
1.53
Extreme 1.53
4.90
1 year
1.53
Extreme 1.53
48.99
3 years
1.53
Extreme 1.53
48.99
5 years
1.53
Extreme 1.53
48.99
10 years
1.53
Extreme 1.53
48.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 41 31/03/18
Founder 54 31/12/14
Director of Finance/CFO 55 31/12/22
Members of the board TitleAgeSince
Director/Board Member 68 31/10/22
Director/Board Member 60 31/03/16
Director/Board Member 68 11-29
More insiders
Date Price Change Volume
16/05/24 2.13 +3.40% 50,460
15/05/24 2.06 +1.48% 51,684
14/05/24 2.03 +6.84% 56,347
13/05/24 1.9 +1.06% 132,490
10/05/24 1.88 -3.59% 156,029

Delayed Quote Nasdaq, May 16, 2024 at 09:30 pm

More quotes
Monogram Orthopaedics Inc. (Monogram) is engaged in developing a product solution architecture that enables patient-optimized orthopedic implants by linking three-dimensional (3D) printing and robotics with advanced pre-operative imaging. Its primary business is to market orthopedic implants insertable with its orthopedic robot. The Company has a robot prototype that can autonomously execute optimized paths for precision insertion of implants in simulated cadaveric surgeries. The Monogram robotic system and related hardware (end-effector) are multi-use capital equipment. The Monogram technology platform consists of a workflow to prepare a patient-specific surgical plan from a computed tomography (CT) scan. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
Calendar
More about the company